Peptides in the EU 2026: Legal Status, Research-Use Classification, WADA List

A small set of peptide-based medicines has been formally authorised by the EMA via the centralised procedure and can be marketed across all EU member states as consumer medicines. As of 2026, that list includes: semaglutide (marketed as Ozempic for type 2 diabetes, Wegovy for chronic weight management, and Rybelsus as an oral formulation); tirzepatide (Mounjaro for type 2 diabetes and weight management, marketed as Zepbound in some jurisdictions); liraglutide (Saxenda for weight management, Victoza for type 2 diabetes); and dulaglutide (Trulicity).^[4][5][6][2]

Tesamorelin (Egrifta SV) is FDA-approved in the United States for HIV-associated lipodystrophy but is not EMA-authorised in any indication — there is no EPAR for tesamorelin and Egrifta is not marketed in EU member states. The asymmetry between FDA and EMA approvals matters for European buyers: 'FDA-approved' does not translate to EU authorisation, and tesamorelin sits in the unauthorised-in-EU category.^[7][8][2]

Insulin analogues (insulin glargine, insulin lispro, insulin aspart, insulin degludec) are peptide medicines authorised through the EMA centralised or national procedures depending on the product. They are not relevant to the research-peptide market but are the largest peptide-medicine category by volume in EU healthcare.^[2]

All EU member states operate within the Directive 2001/83 framework, but each has its own medicines authority that handles national licensing, enforcement, and personal-import rules. In the Netherlands, the College ter Beoordeling van Geneesmiddelen (CBG-MEB) is the national authority, working with the Inspectie Gezondheidszorg en Jeugd (IGJ) on enforcement. In Germany, the Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM) is the national authority, with strong enforcement on unauthorised medicinal products entering the country.^[9][10]

In France, the Agence nationale de sécurité du médicament et des produits de santé (ANSM) is the national authority and tends to enforce strictly on personal-import volumes that exceed clear personal-research thresholds. In Belgium, the Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten (FAGG-AFMPS) operates similarly. In Spain (AEMPS) and Italy (AIFA), national enforcement is in place but operational details vary by region.^[11][2]

The practical effect for buyers is that 'legal in the EU' is a useful but coarse statement. Within the EU framework, national authorities can and do exercise discretion on personal-import volumes, customs inspections, and the line between research possession and de-facto consumer use. A buyer should know their own national authority and the rules it actually applies.^[9][10][11]

The World Anti-Doping Agency's 2026 Prohibited List Internal Standard categorises substances prohibited in competitive sport. Section S2 covers peptide hormones, growth factors, related substances, and mimetics. Section S2 explicitly includes growth hormone and its releasing factors (GHRH and its analogues including sermorelin, tesamorelin, CJC-1295), growth hormone secretagogues including MK-677 (ibutamoren) and the GHRP/ipamorelin family, IGF-1 and its analogues including IGF-1 LR3, and GLP-1 receptor agonists including semaglutide and tirzepatide when used outside their approved therapeutic context.^[13][14]

Section S0 (Non-Approved Substances) is the catch-all category for pharmacological substances with no current approval by any governmental regulatory health authority for human therapeutic use. BPC-157 was added to S0 in the 2022 WADA list update and remains in S0 on the 2026 list. Substances in S0 are prohibited at all times — there is no in-competition / out-of-competition distinction.^[16][13]

For athletes subject to anti-doping testing — Olympic-pathway, professional-league, or national-federation contracted — the operational rule is straightforward: any peptide hormone, growth factor, or mimetic should be treated as prohibited unless a Therapeutic Use Exemption (TUE) has been formally granted by the relevant anti-doping authority. The TUE process requires documented medical necessity and approved pre-competition paperwork.^[15][13]

Within the EU single market, free movement of goods applies in principle, but medicinal products are explicitly carved out as a regulated category under Directive 2001/83 and the EU customs prohibitions framework. A product authorised in one EU member state is generally recognised in others through mutual-recognition procedures, but an unauthorised research peptide does not benefit from free movement as a medicine — it crosses borders as a research chemical, subject to national customs rules and personal-import thresholds.^[1][12]

Imports from outside the EU customs territory face additional layers. The EU customs prohibitions and restrictions framework covers personal-use medicinal-product imports, with member-state-level rules determining what quantities qualify as personal use versus commercial import. Importing an unauthorised peptide from outside the EU into a member state may face customs interception even when the substance is sold as a research compound at origin.^[12][2]

The honest summary for a European buyer is: buying from a vendor based in the EU and shipping within the EU is operationally simpler than importing from outside the EU, both for regulatory compliance and for delivery reliability. The medicinal-product carve-out from free movement is real, but intra-EU shipment of research-classified compounds is the more straightforward path.^[1][12]

Possessing an unauthorised research peptide for laboratory or personal research investigation, in quantities consistent with research rather than commercial supply, is the operational space the consumer-research peptide market occupies in most EU member states. The frame is: held as a research compound, not as a medicine; not advertised for human therapeutic use; not redistributed commercially. Within those operating limits, possession sits in a regulatory grey zone that varies by member state but is not generally prosecuted as drug-trafficking or medicines-law offence at personal-research volumes.^[1][3]

What buyers cannot legally do is the more useful list. Cannot: advertise medical claims; redistribute commercially; market for human therapeutic use; bypass customs at large-volume commercial scale; falsify import declarations. The 'for research use only' designation must be substantively honoured, not just stickered on a label.^[1][12]

Buyers who are clinical researchers, biotech employees, or working under an institutional research framework operate inside a different regulatory layer — Good Clinical Practice (GCP), Good Manufacturing Practice (GMP), ethics-committee approval, and institutional supply chains — that is outside the scope of the consumer-research market entirely. The consumer-research category is for personal investigation, not institutional clinical research.^[3][17]

For competitive athletes, the WADA framework is the operational rule rather than the medicines-law framework. Any peptide hormone, growth factor, or mimetic should be treated as prohibited in competition unless a Therapeutic Use Exemption has been formally granted. The TUE process requires documented medical necessity, prescription from a treating physician, and pre-competition paperwork filed with the relevant National Anti-Doping Organisation or international federation.^[15][13]

Even legally purchased, EMA-authorised peptide medicines (semaglutide for diagnosed obesity, for example) can produce a positive anti-doping test if used by a competitive athlete without an approved TUE. The medicines-law authorisation does not override the anti-doping framework — they are separate regulatory systems with separate compliance requirements.^[15][4]

Penalties for adverse analytical findings in competitive sport range from competition disqualification to multi-year bans depending on the substance, the level of intent, and the federation. The WADA list is not advisory — it is the controlling rule for testing pools, and athletes carry strict liability for what is in their bodies regardless of how it got there.^[13][15]